Direct Healthcare Professional Communication (DHPC) on Clozapine: Revised recommendations for routine blood count monitoring with regard to the risk of agranulocytosis
2025.09.08
Active substance: clozapine
In agreement with the European Medicines Agency (EMA) and the Federal Institute for Drugs and Medical Devices (BfArM), the marketing authorisation holders of clozapine-containing medicinal products are providing information on the revised recommendations for routine blood count monitoring to minimise the risk of neutropenia and agranulocytosis with clozapine.
Download DHPC/Information letter , Download_VeroeffentlichtAm_EN